

PubMed

Search: jak2 mutation valine

U.S. National Library of Medicine
National Institutes of Health

Filter your results: All (56)

[Manage Filters](#)

Display Settings: Summary, 20 per page, Sorted by Recently Added

Results: 41 to 56 of 56

41. [\[Mutation of protein kinase JAK2 in polycythemia vera: new perspectives in physiopathology and therapy\]](#)
Marie I, Hervé F.
Rev Med Interne. 2006 Jun;27(6):473-7. Epub 2006 Mar 30. Review. French.
PMID: 16531280 [PubMed - indexed for MEDLINE]
42. [The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation.](#)
Jamieson CH, Gotlib J, Durocher JA, Chao MP, Mariappan MR, Lay M, Jones C, Zehnder JL, Lilleberg SL, Weissman IL.
Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6224-9. Epub 2006 Apr 7.
PMID: 16503627 [PubMed - indexed for MEDLINE]
[Free article](#)
43. [A longitudinal study of the JAK2\(V617F\) mutation in myelofibrosis with myeloid metaplasia: analysis at two time points.](#)
Mesa RA, Powell H, Lasho T, DeWald GW, McClure R, Tefferi A.
Haematologica. 2006 Mar;91(3):415-6.
PMID: 16531268 [PubMed - indexed for MEDLINE]
[Free article](#)
44. [The incidence of the JAK2 V617F mutation in patients with idiopathic erythrocytosis.](#)
Percy MJ, Jones FG, Green AR, Reilly JT, McMullin MF.
Haematologica. 2006 Mar;91(3):413-4. Epub 2006 Feb 17.
PMID: 16503548 [PubMed - indexed for MEDLINE]
[Free article](#)
45. [The effect of the JAK2 V617F mutation on PRV-1 expression.](#)
Mnjoyan Z, Yoon D, Li J, Delhommeau F, Afshar-Kharghan V.
Haematologica. 2006 Mar;91(3):411-2. Epub 2006 Feb 17.
PMID: 16503546 [PubMed - indexed for MEDLINE]
[Free article](#)
46. [\[Acquired mutation of JAK2 tyrosine kinase and polycythaemia vera\]](#)
Pargade V, Darnige L, Gaussem P.
Ann Biol Clin (Paris). 2006 Jan-Feb;64(1):3-9. Review. French.
PMID: 16420986 [PubMed - indexed for MEDLINE]
47. [The V617F JAK2 mutation and the myeloproliferative disorders.](#)
Percy MJ, McMullin MF.
Hematol Oncol. 2005 Sep-Dec;23(3-4):91-3. Review.
PMID: 16285006 [PubMed - indexed for MEDLINE]
48. [Role of tyrosine kinases and phosphatases in polycythemia vera.](#)
Zhao ZJ, Vainchenker W, Krantz SB, Casadevall N, Constantinescu SN.
Semin Hematol. 2005 Oct;42(4):221-9. Review.
PMID: 16210035 [PubMed - indexed for MEDLINE]
49. [Chromosomal abnormalities and molecular markers in myeloproliferative disorders.](#)
Bench AJ, Pahl HL.
Semin Hematol. 2005 Oct;42(4):196-205. Review.

PMID: 16210033 [PubMed - indexed for MEDLINE]

50. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders.
Scott LM, Campbell PJ, Baxter EJ, Todd T, Stephens P, Edkins S, Wooster R, Stratton MR, Futreal PA, Green AR.
Blood. 2005 Oct 15;106(8):2920-1. No abstract available.
PMID: 16204151 [PubMed - indexed for MEDLINE]
[Free article](#)
51. The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis.
Tefferi A, Gilliland DG.
Mayo Clin Proc. 2005 Jul;80(7):947-58. Review.
PMID: 16007902 [PubMed - indexed for MEDLINE]
[Free article](#)
52. The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients.
Goerttler PS, Steimle C, März E, Johansson PL, Andreasson B, Griesshammer M, Gisslinger H, Heimpel H, Pahl HL.
Blood. 2005 Oct 15;106(8):2862-4. Epub 2005 Jun 28.
PMID: 15985544 [PubMed - indexed for MEDLINE]
[Free article](#)
53. Identification of an acquired JAK2 mutation in polycythemia vera.
Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, Zhao ZJ.
J Biol Chem. 2005 Jun 17;280(24):22788-92. Epub 2005 Apr 29.
PMID: 15853514 [PubMed - indexed for MEDLINE]
[Free article](#)
54. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC.
N Engl J Med. 2005 Apr 28;352(17):1779-90.
PMID: 15858187 [PubMed - indexed for MEDLINE]
[Free article](#)
55. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.
James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W.
Nature. 2005 Apr 28;434(7037):1144-8.
PMID: 15793561 [PubMed - indexed for MEDLINE]
56. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR; Cancer Genome Project.
Lancet. 2005 Mar 19-25;365(9464):1054-61. Erratum in: Lancet. 2005 Jul 9-15;366(9480):122.
PMID: 15781101 [PubMed - indexed for MEDLINE]